Phase 3, randomized trial (CheckMate 057) of nivolumab vs docetaxel in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): subgroup analyses and patient reported outcomes (PROs)

被引：0
作者：
Horn, L. [1 ]
Brahmer, J. [2 ]
Reck, M. [3 ]
Borghaei, H. [4 ]
Spigel, D. R. [5 ]
Steins, M. [6 ]
Ready, E. [7 ]
Chow, L. Q. [8 ]
Vokes, E. E. [9 ]
Felip, E. [10 ]
Holgado, E. [11 ]
Barlesi, F. [12 ]
Kohlhaeufl, M. [13 ]
Burgio, M. A. [14 ]
Fayette, J. [15 ]
Gettinger, S. N. [16 ]
Harbison, C. T. [17 ]
Li, A. [18 ]
Finckenstein, F. G. [19 ]
Paz-Ares, L. [20 ]
机构：
[1] Vanderbilt Ingram Canc Ctr, Dept Med, Nashville, TN USA
[2] Johns Hopkins Univ Hosp, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21287 USA
[3] LungenClin Grosshansdorf, Grosshansdorf, Germany
[4] Fox Chase Canc Ctr, Med Oncol, Philadelphia, PA 19111 USA
[5] Sarah Cannon Res Inst, Ctr Canc, Med Oncol, Nashville, TN USA
[6] Thoraxklin Heidelberg, Internal Med Oncol, Heidelberg, Germany
[7] Duke Univ, Med Ctr, Div Oncol, Durham, NC USA
[8] Univ Washington, Dept Med, Seattle Canc Care Alliance, Seattle, WA USA
[9] Univ Chicago, Med Ctr, Dept Med, Chicago, IL 60637 USA
[10] Vall dHebron Univ Hosp, Dept Oncol, Barcelona, Spain
[11] Hosp Madrid Norte, San Chinarro Ctr Integral Oncol Clara Campal, Serv Oncol, Madrid, Spain
[12] Hop Nord Marseille, Multidisciplinary Oncol & Therapeut Innovat, Marseille, France
[13] Klin Schillerhohe, Pneumonol & Pulm Oncol, Gerlingen, Germany
[14] Ist Sci Romagnolo Studio & Cura Tumori, Dept Med Oncol, Meldola, Italy
[15] Ctr Leon Berard, Oncol Med, F-69373 Lyon, France
[16] Yale Univ, Sch Med Med Oncol, Med Oncol, New Haven, CT USA
[17] Bristol Myers Squibb Co, ImmunoSci Metab Dis & Fibrosis, Princeton, NJ USA
[18] Bristol Myers Squibb Co, Oncol, Princeton, NJ USA
[19] Bristol Myers Squibb Co, Oncol Global Clin Res, Princeton, NJ USA
[20] Hosp Univ Virgen del Rocio, Serv Oncol Med, Seville, Spain
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
417O
引用
收藏
页码：125 / 125
页数：1
相关论文
共 50 条
  • [41] Is pemetrexed more effective in patients with non-squamous histology? A retrospective analysis of a phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC)
    Peterson, P.
    Park, K.
    Fossella, F.
    Gatzemeier, U.
    John, W.
    Scagliotti, G.
    EJC SUPPLEMENTS, 2007, 5 (04): : 363 - 364
  • [42] A phase II trial of weekly cisplatin and docetaxel in advanced non-small cell lung cancer (NSCLC)
    Sovak, M. A.
    Lutzker, S.
    Guensch, L.
    Joyce, M.
    Schwartz, S.
    Wu, Y.
    Zheng, L.
    Aisner, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [43] Evaluation of overall health status in patients with advanced squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 017
    Reck, M.
    Coon, C.
    Taylor, F.
    DeRosa, M.
    Penrod, J. R.
    Dastani, H.
    Orsini, L.
    Gralla, R. J.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S599 - S600
  • [44] Overall health status (HS) in patients (pts) with advanced (adv) non-squamous (NSQ) NSCLC treated with nivolumab (nivo) or docetaxel (doc) in CheckMate 057
    Reck, M.
    Brahmer, J.
    Bennett, B.
    Taylor, F.
    Penrod, J. R.
    Derosa, M.
    Dastani, H.
    Gralla, R.
    ANNALS OF ONCOLOGY, 2016, 27
  • [45] Checkmate 384: A Phase 313/4 Dose Frequency Optimization Trial of Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
    Harris, Ronald
    Reinmuth, Niels
    Mitche, Paul
    Zhu, Jin
    Chang, I-Fen
    Pichons, Eric
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1298 - S1299
  • [46] COST-ANALYSIS FOR TOXICITY MANAGEMENT IN ADVANCED SQUAMOUS NON-SMALL CELL LUNG CANCER: NIVOLUMAB VS DOCETAXEL
    Ortega-Joaquin, N.
    Echave, M.
    Oyaguez, I
    Garrido, P.
    Felip, E.
    Trigo, J.
    Filori, M.
    Gonzalez Garcia, P.
    VALUE IN HEALTH, 2016, 19 (07) : A722 - A722
  • [47] AdvanTIG-105: Phase Ib dose-expansion study of ociperlimab (OCI) plus tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with metastatic squamous (sq) and non-squamous (non-sq) non-small cell lung cancer (NSCLC)
    Yu, Y.
    Huang, D.
    Gao, B.
    Zhao, J.
    Hu, Y.
    Zhuang, W.
    Kao, S.
    Xu, W.
    Yao, Y.
    Yang, T-Y.
    Lee, Y.
    Kim, J-S.
    Shiah, H-S.
    Wang, R.
    Zheng, H.
    Tan, W.
    Gao, R.
    Kim, H. R.
    Lu, S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1019 - S1019
  • [48] Retrospective evaluation of chemotherapy options in non-squamous non-small cell lung cancer (non-Sq NSCLC) patients (pts) unfit for standard platinum-based chemotherapy in clinical practice
    Cortellini, A.
    Bruera, G.
    Sarno, I.
    Baldi, P. Lanfiuti
    Cannita, K.
    Dal Mas, A.
    Marchetti, A.
    Ficorella, C.
    Ricevuto, E.
    ANNALS OF ONCOLOGY, 2015, 26 : 87 - 87
  • [49] Overall health status (HS) in patients (pts) with advanced (adv) non-squamous (NSQ) NSCLC treated with nivolumab (nivo) or docetaxel (doc) in CheckMate 057
    Reck, M.
    Brahmer, J. R.
    Bennett, B.
    Taylor, F.
    Penrod, J. R.
    Derosa, M.
    Dastani, H.
    Gralla, R.
    ANNALS OF ONCOLOGY, 2016, 27
  • [50] Nivolumab: A Review in Advanced Squamous Non-Small Cell Lung Cancer
    Gillian M. Keating
    Drugs, 2015, 75 : 1925 - 1934
12345